- Home
- SEDG vs MNKD Comparison
SEDG vs MNKD Comparison
Compare SEDG & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEDG
- MNKD
- Stock Information
- Founded
- SEDG 2006
- MNKD 1991
- Country
- SEDG Israel
- MNKD United States
- Employees
- SEDG N/A
- MNKD N/A
- Industry
- SEDG Semiconductors
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SEDG Technology
- MNKD Health Care
- Exchange
- SEDG Nasdaq
- MNKD Nasdaq
- Market Cap
- SEDG 1.5B
- MNKD 1.7B
- IPO Year
- SEDG 2015
- MNKD 2004
- Fundamental
- Price
- SEDG $37.84
- MNKD $5.30
- Analyst Decision
- SEDG Sell
- MNKD Strong Buy
- Analyst Count
- SEDG 20
- MNKD 5
- Target Price
- SEDG $21.71
- MNKD $10.80
- AVG Volume (30 Days)
- SEDG 3.4M
- MNKD 4.4M
- Earning Date
- SEDG 11-05-2025
- MNKD 11-05-2025
- Dividend Yield
- SEDG N/A
- MNKD N/A
- EPS Growth
- SEDG N/A
- MNKD 149.32
- EPS
- SEDG N/A
- MNKD 0.11
- Revenue
- SEDG $940,561,000.00
- MNKD $301,736,000.00
- Revenue This Year
- SEDG $34.78
- MNKD $14.78
- Revenue Next Year
- SEDG $16.05
- MNKD $19.36
- P/E Ratio
- SEDG N/A
- MNKD $48.98
- Revenue Growth
- SEDG N/A
- MNKD 21.48
- 52 Week Low
- SEDG $10.24
- MNKD $3.38
- 52 Week High
- SEDG $41.92
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SEDG 51.54
- MNKD 48.76
- Support Level
- SEDG $35.81
- MNKD $5.21
- Resistance Level
- SEDG $41.73
- MNKD $5.62
- Average True Range (ATR)
- SEDG 3.03
- MNKD 0.25
- MACD
- SEDG -0.17
- MNKD -0.02
- Stochastic Oscillator
- SEDG 47.01
- MNKD 56.05
About SEDG SolarEdge Technologies Inc.
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.